Anika Therapeutics | ANIK - SCHULD





SCHULD Veränderung Datum
Abbott USD 13.86B 919M 2025-12
Agenus USD 35.54M 2.34M 2025-03
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Anika Therapeutics USD 0 0 2025-03
Arrowhead Research USD 312.77M 53.52M 2025-12
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Heron Therapeutics USD 149.65M 157K 2024-09
Insmed USD 727.62M 275K 2026-03
Integra LifeSciences USD 2.04B 6.27M 2026-03
Intrexon USD 0 13.82M 2024-06
J&J USD 47.93B 2.14B 2025-12
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Ligand Pharmaceuticals USD 451.49M 494K 2025-12
MacroGenics USD 36.51M 500K 2026-03
Merit Medical Systems USD 821.57M 420K 2025-12
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 20.33B 1.43B 2025-12
Smith & Nephew USD 3.32B 334M 2024-12
Stryker USD 14.22B 635M 2026-03
Veracyte USD 39.65M 799K 2025-12
Xencor USD 187.75M 118.48M 2025-12
Zimmer Biomet Holdings USD 7.47B 48.1M 2026-03